Home Cart Sign in  
Chemical Structure| 528-53-0 Chemical Structure| 528-53-0

Structure of Delphinidin chloride
CAS No.: 528-53-0

Chemical Structure| 528-53-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Delphinidin chloride is an anthocyanidin isolated and purified from the fruits of Vaccinium myrtillus which serves as the precursor of certain anthocyanins that provide the blue-red colors of flowers, fruits, and red wine.

Synonyms: Delphinidin (chloride); Ephdine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Delphinidin chloride

CAS No. :528-53-0
Formula : C15H11ClO7
M.W : 338.70
SMILES Code : OC1=C(O)C(O)=CC(C2=C(O)C=C3C(O)=CC(O)=CC3=[O+]2)=C1.[Cl-]
Synonyms :
Delphinidin (chloride); Ephdine
MDL No. :MFCD00016663

Safety of Delphinidin chloride

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Delphinidin chloride

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
22R ν1 cells 30–180 μmol/L 48 h To evaluate the effect of Delphinidin on 22R ν1 cell growth, results showed that Delphinidin inhibited cell growth in a dose-dependent manner. Cancer Res. 2008 Oct 15;68(20):8564-72
C4-2 cells 30–180 μmol/L 48 h To evaluate the effect of Delphinidin on C4-2 cell growth, results showed that Delphinidin inhibited cell growth in a dose-dependent manner. Cancer Res. 2008 Oct 15;68(20):8564-72
LNCaP cells 30–180 μmol/L 48 h To evaluate the effect of Delphinidin on LNCaP cell growth, results showed that Delphinidin inhibited cell growth in a dose-dependent manner. Cancer Res. 2008 Oct 15;68(20):8564-72
PC3 cells 30–180 μmol/L 48 h To evaluate the effect of Delphinidin on PC3 cell growth, results showed that Delphinidin inhibited cell growth and induced apoptosis in a dose-dependent manner. Cancer Res. 2008 Oct 15;68(20):8564-72
Human small airway epithelial (SAE) cells 0.1–10 μM 24 h Evaluate the inhibitory effect of Delphinidin on IL-8 production. In non-treated SAE cells, IL-8 levels were unchanged; in CSE-treated cells, Delphinidin significantly inhibited IL-8 production in a dose-dependent manner (1 μM and 10 μM). Food Chem. 2012 Oct 1;134(3):1256-62
human aortic VSMCs 10-100 μM 30 min Inhibited PDGF AB-induced VEGF release by preventing activation of p38 MAPK and JNK Br J Pharmacol. 2006 Oct;149(3):283-90
C28/I2 human chondrocytes 40 µM 4 h To assess the protective effect of delphinidin against oxidative stress-induced apoptosis in chondrocytes. Results showed that delphinidin significantly decreased apoptosis markers c-caspase-3 and c-PARP while increasing antiapoptotic marker Bcl-XL and antioxidant response proteins Nrf2 and NF-κB. Antioxidants (Basel). 2020 Jan 19;9(1):83
C28/I2 human chondrocytes 10–75 µM 2 h, 4 h, 24 h To evaluate the cytotoxic effect of delphinidin on chondrocytes. Results showed that delphinidin at concentrations below 50 µM did not significantly affect chondrocyte viability after 24 h. Antioxidants (Basel). 2020 Jan 19;9(1):83

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic nude mice PC3 cell xenograft model Intraperitoneal injection 2 mg/animal Thrice weekly for 8 weeks To evaluate the effect of Delphinidin on PC3 cell xenograft tumor growth, results showed that Delphinidin significantly inhibited tumor growth. Cancer Res. 2008 Oct 15;68(20):8564-72
Mice Flaky skin mouse model Topical application 0.5 mg/cm² and 1 mg/cm² Five times a week, up to 14 weeks of age Reduced pathological markers of psoriasiform lesions, induced epidermal differentiation, reduced keratinocyte proliferation and inflammation Br J Dermatol. 2015 Feb;172(2):354-64

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02006394 Insulin Resistance ... More >> Obesity Metabolic Syndrome Less << Not Applicable Completed - United States, California ... More >> University of California, San Diego San Diego, California, United States, 92093 Less <<
NCT03485885 - Completed - Germany ... More >> Nutritional CRO & Study site; BioTeSys GmbH Esslingen, Baden-Württemberg, Germany, 73728 Less <<
NCT03213288 Hyperlipidemia Not Applicable Active, not recruiting December 2019 United Kingdom ... More >> Quadram Institute Bioscience Norwich, United Kingdom, NR4 7UA Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.95mL

0.59mL

0.30mL

14.76mL

2.95mL

1.48mL

29.52mL

5.90mL

2.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories